Trimeris Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (27)

Latest Posts

About This Stock More About This Stock
Insiders And The New Medicine
Article By: Bruce Pile
Sunday, March 5, 2017 3:05 PM EDT
Biotech was the big outperformer for years up until mid 2015. After a big cool down, it looks to be reigniting.
In this article: GEVA, INCY, PCYC, SGEN
Read
5 Healthy Stocks In The Top Biotech ETF
Article By: Zacks Investment Research
Wednesday, June 17, 2015 1:42 PM EDT
The pharma stocks are soaring, but the biotech is the real winner, having emerged as a leader yet gain in the health care world and the broader market from the year-to-date look.
In this article: ANAC, GEVA, HALO, HZNP, IMGN Also: SBIO
Read
Biotechs Tag Along With Broad Market Rally: FBT Up 3%
Article By: Rod Raynovich
Friday, May 8, 2015 5:17 PM EDT
Stocks moved higher on the “goldilocks” job report which showed a gain of 223k added in April. The jobs number was too high to raise concerns about an increase in rates but not too bullish because overall productivity is down.
In this article: XBI, ALXN, GEVA, BIIB, AMGN, REGN, ALKS, CLVS, SGEN, BMRN, ALNY, VRTX, FBT, GILD Also: ABBV, PCYC, MRK, CBST, BLUE, JUNO, KITE, ZIOP, AGIO, ARIA
Read
E Alexion Pharmaceuticals Buys Synageva For $8.4B; One Stock Falls, The Other Soars
Article By: Terry Chrisomalis
Wednesday, May 6, 2015 10:28 PM EDT
Shares of Alexion fell 13.5% for the day after acquiring Synageva for a 140% premium.
In this article: ALXN, GEVA
Read
M&A Sparks Biotechs: Alexion Buys Synageva For $8.4B…Update-1
Article By: Rod Raynovich
Wednesday, May 6, 2015 6:40 PM EDT
An issue for rare disease companies down the road is pricing as government agencies may question spending hundreds of thousands of dollars per year for one patient. But the number of patients are very small in the 10,000 range...
In this article: ALXN, GEVA, BMRN
Read

PARTNER HEADLINES

Latest Tweets for $GEVA

No tweets yet!